Nobel prize 'horse paste' that costs 3c/dose reduces Covid death by 70%, infections by 44%

Two gigantic studies were just released on the use of Ivermectin against Sars-CoV-2.

Full video breakdown here:

Video


Full studies here:

LINK

LINK

LINK


One study directly compared it against Remdesivir as it equates to deaths among those infected. The 18-month study was peer reviewed and controlled by clinical and hospital health care pros across the US and included 42,000 patients.

A second study showed the effects of ivermectin as a low dose Prophylaxis (preventative) for an entire city in Brazil over a 6-month period.

The study included 225,000 people.

Reminder: Ivermectin won the Nobel prize in 2015 and is listed as an "essential medicine" by the Who. That means it's for people.

It is also a key ingredient in many veterinary applications because it is such a good anti-parasitic.

It also has shown to have strong anti-viral properties in humans.

It's costs about 3 cents per dose and is made en masse in India and other countries. It has been administered over 1 billion times around the world over the last 40 years with virtually zero side effects or adverse reactions.

This medication has been called the devil and 'horse paste' for 2 years by almost every corporate and medical power structure that exists.





1st Study - Mortality compared to Remdisivir

quote:

---

To evaluate the difference in mortality,

Patients treated with ivermectin

Patients treated with remdesivir

44 healthcare organizations and 68 million patients from US, January 1, 2020 and July 11, 2021

Methods & Materials Retrospectively identified diagnosed adults


Recorded use of ivermectin, but not remdesivir Recorded use of remdesivir, but not ivermectin Controlled for, comorbidities, and treatments that may affect COVID-19 survival outcomes: age, gender, race, ethnicity, nicotine use diabetes mellitus, obesity, chronic lower respiratory disease, ischemic heart diseases, tocilizumab, glucocorticoids, or ventilator use.

Primary outcome assessed, mortality


Sith significance assessed at p less than 0.05.

Result 41,608 patients who had COVID-19

Treated with ivermectin n = 1,072

Treated with remdesivir n = 40,536

Ivermectin was associated with reduced mortality vs remdesivir OR 0.308 p less than 0.0001.



That means that people with covid who were treated with Ivermectin died at a 70% lower rate than those treated with Remdisivir. Which costs $300/dose and was pushed by Anthony Fauci, who owns stock in the company.


Conclusion Ivermectin use was associated with decreased mortality in patients with COVID-19 compared to remdesivir.


In the future, if more publications are published with the similar result to the current analyses, the certainty of evidence will increase.


....





2nd Study - Prophylaxis




[quote]
Ivermectin Prophylaxis Used for COVID-19: A Citywide, Prospective, Observational Study of 223,128 Subjects Using Propensity Score Matching (Brazil)



Background:

Ivermectin has demonstrated different mechanisms of action, coronavirus infection and COVID-19-related comorbidities. Prophylaxis combined with the known safety profile of ivermectin Study to evaluate the impact of regular ivermectin use on subsequent COVID-19 infection and mortality rates.

Prospective, July 2020 and December 2020 Inviting the entire population of Itajaí to a medical visit to enroll in the program, ivermectin was offered as an optional treatment to be taken for two consecutive days every 15 days at a dose of 0.2 mg/kg/day.


Study analysis consisted of comparing ivermectin users with non-users using cohorts



Results


223,128 citizens of Itajaí considered 159,561 included in the analysis 113,845 (71.3%) regular ivermectin users 45,716 (23.3%) non-users


Of these 4,311 ivermectin users were infected, (3.7% infection rate)

3,034 non-users (6.6% infection rate)

A 44% reduction in COVID-19 infection rate Risk ratio (RR), 0.56

The regular use of ivermectin led to a 68% reduction in COVID-19 mortality

Deaths 25 (0.8%) deaths in the ivermectin group 79 (2.6%) among ivermectin non-users RR, 0.32 p less than 0.0001


When adjusted for residual variables, reduction in mortality rate was 70%


There was a 56% reduction in hospitalization rate 44 in the ivermectin group 99 in non ivermectin users


After adjustment for residual variables, reduction in hospitalization rate was 67% p less than 0.0001


Conclusion In this large study, regular use of ivermectin as a prophylactic agent was associated with significantly reduced COVID-19 infection, hospitalization, and mortality rates.

---

People should be in jail.